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Poster Session-II 115the basis of significant epidermal hyperplasia, dyskeratosis, dermal fi-
brosis with hemorrhage, loss of hair follicles and sebaceious glands,
inflammation of subcutaneous fat tissue and hemorrhagic cysts.
These findings confirmed that GvHD could be induced using the
macaquemodel. The third animal was transplanted with haploident-
ical donor bone marrow (1.1 109 total nucleated cells/kg and 6.9
107 CD31 T cells/kg), but was given T cell costimulation blockade
with abatacept (targeting the CD28/B7 pathway) and an anti-CD40
antibody (targeting the CD40/CD154 pathway) in addition to rapa-
mycin. Abatacept is currently clinically approved for treatment of
rheumatoid arthritis, but has not been added to clinical GvHD reg-
imens, largely due to the paucity of translational efficacy data. This
animal maintained full donor chimerism (including 100% T and B
cell chimerism), until day 63 when he was sacrificed, without signs
of GvHD. Additional animals are now being added to the study, to
confirm these initial results.
Conclusions: 1. We have established a robust non-human pri-
mate model of GvHD using pedigreed and MHC-typed rhesus ma-
caques. 2. We have used this model to begin to test the efficacy of
a novel agent combination, capable of preventing the onset and com-
plications of acute GvHD. 3. Preliminary results suggest that CD28-
and CD40-directed costimulation blockade may be active agents for
the prevention of GvHD. A large scale analysis of their efficacy and
immune consequences is currently underway.320
EVALUATION OF OPTIMAL BLOOD CONCENTRATION OF TACROLIMUS
FOR THE PROPHYLAXIS OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM
UNRELATED DONOR
Mori, T., Aisa, Y., Kato, J., Nakamura, Y., Ikeda, Y., Okamoto, S. Keio
University School of Medicine, Tokyo, Japan
Background: Optimal blood concentration of tacrolimus for the
prophylaxis of GVHD after allogeneic hematopoietic stem cell
transplantation (HSCT) has not been established. Our retrospective
analysis has shown that incidence of Grades II-IV acute GVHD in
patients with mean tacrolimus concentration less than 15 ng/ml
was significantly higher than that in patients with mean tacrolimus
concentration 15 ng/ml or higher. The present study has set the tar-
get tacrolimus concentration between 15 and 20 ng/ml, and evalu-
ated the efficacy in preventing the development of acute GVHD
after allogeneic HSCT from unrelated donor.
Patients and Methods: Patients undergoing allogeneic HSCT
from an HLA-serologically matched unrelated donor for hemato-
logical diseases were evaluated. Stem cell source was bone marrow
in all patients. For the prophylaxis of GVHD, tacrolimus and meth-
otrexate were administered. Tacrolimus was given at an initial dose
of 0.03 mg/kg by continuous intravenous infusion from day -1, and
its dose was arranged to maintain its blood level at 15–20ng/ml dur-
ing the first 4 weeks after HSCT.MTXwas given at a dose of 15mg/
m2 on day 1, and 10 mg/m2 on days 3, 6, and 11.
Results: Of the 55 evaluated patients, 20 (36.4%) patients devel-
oped grade II, 2 patients (3.6%) developed grade III, and no patient
developed grade IV acute GVHD. In multivariate analysis, HLA al-
lele mismatch was an only identified risk factor for developing grades
II-IV acute GVHD, while blood concentration of tacrolimus was
not. No serious complications resulting in discontinuation of tacro-
limus were observed.
Conclusions:Tacrolimuscombinedwithmethotrexatecouldeffec-
tively prevent the development of severe acuteGVHD after allogeneic
HSCT from unrelated donor by maintaining its blood concentration
between 15 and 20 ng/ml in the early post-transplant period.321
VISUALIZING THE FATE OF FOXP3 PROTEIN IN HUMAN T-CELLS
Magg, T., Albert, M.H. Dr. von Haunersches Kinderspital der Universi-
taet Muenchen, Munich, Germany
Foxp3 plays a pivotal role in the development and function of reg-
ulatory T cells (Treg) which represent a promising tool for trans-
plantation tolerance induction. In murine but not human T cells,
forced expression of Foxp3 converts naive T cells into functional
Tregs. This might in part be due to the fact that Foxp3 proteinexpression is difficult to track because endogenous Foxp3 is also ex-
pressed in activated human T-cells. We therefore intended to track
the fate of ectopically expressed Foxp3 protein in humanCD41 cells
with the aim of defining why forced Foxp3 overexpression was not
sufficient for gaining regulatory function and to learn about the
physiological regulation of Foxp3 protein in human T cells. We
used a non-viral nucleofection protocol for transfection of human
CD41 cells with a dual-expression plasmid of a GFP-Foxp3 fusion
protein and a truncated low affinity nerve growth factor receptor
(LNGFR) to allow for positive selection of transfected cells. As ex-
pected we could demonstrate that purified, transiently Foxp3 trans-
fected cells only weakly suppressed proliferation of T cells. We
found that the ectopically expressed Foxp3 protein disappeared
more quickly than Foxp3mRNA levels which remained at high levels
for up to 4 days. Also in stably transfected T cell lines GFP-Foxp3
mRNA but not the fusion protein was detectable. We hypothesized
that this might be due to posttranslational protein degradation or
posttranscriptionally decreased protein synthesis. We observed ap-
pearance of Foxp3 protein in stably transfected Jurkat cells treated
with the proteasome inhibitor bortezomib implying ubiquitinylation
as one mechanism of Foxp3 protein degradation. By fluorescent mi-
croscopy we could demonstrate that Foxp3 was relocated from the
nucleus to the cytoplasm within 24 hours after transfection. Using
a plasmid encoding for a Foxp3 protein double-tagged with N-ter-
minal GFP and C-terminal YFP we found that the GFP tagged frag-
ment was relocated to the cytoplasm and disappeared after 4 days,
while the YFP tagged fragment remained in the nucleus. Both a nu-
clear import and a nuclear export motif in the coding sequence of
Foxp3 could be identified. Our findings demonstrate that human
Foxp3 protein expression is subject to a regulatory pathway control-
ling subcellular distribution as well as protein stability. This experi-
mental setup should provide a basis for further conclusions about the
natural biology of this important determinator of Treg function.322
HIGH BAFF:B CELL RATIOS AND CIRCULATING ACTIVATED B CELLS IN
CHRONIC GVHD
Sarantopoulos, S.1, Stevenson, K.E.2, Kim, H.T.2, Cutler, C.S.1,
Bhuiya, N.S.1, Schowalter, M.1, Ho, V.T.1, Joseph, S.J.1, Antin, J.H.1,
Jerome, R.1 1Dana-Farber Cancer Institute, Boston, MA; 2Dana-Farber
Cancer Institute, Boston, MA
Although rituximab is an effective treatment for steroid refractory
chronic GVHD (cGVHD), the mechanisms underlying B cell in-
volvement in cGVHD have not been elucidated. Previous studies
have demonstrated that patients with active cGVHDhave high levels
of BAFF, a pivotal B cell survival cytokine. We hypothesized that B
cell reconstitution in the context of high BAFF after HSCT could
support activated, potentially pathologic B cell populations that are
most dependent on BAFF for survival. We first performed detailed
phenotypic and functional analyses of peripheral B cells in 57 patients
.12 month post-HSCT and 33 healthy controls (see table).
BAFF:
Patient
Group
(median
month
post-HSCT)
(B Cell
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ng BAFF/
1000
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vs. no
cGVHD (Median
Naive B
Cell
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vs. no
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T
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n5330.008 0.48 89.5 0.0004 14.4 0.02No cGVHD
(27 mo.)
n5120.008 260.5 28.7Inactive
cGVHD
(31 mo.)
n5230.026 0.01 99.1 0.0005 8.5 0.04Active
cGVHD
(21 mo.)
n5220.046 \0.0001 79.8 0.0009 8.1 0.04
